Baseline serum interleukin-6 to interleukin-2 ratio is associated with the response to seasonal trivalent influenza vaccine in solid organ transplant recipients
Copyright © 2015 Elsevier Ltd. All rights reserved..
BACKGROUND: The analysis of pre- and post-vaccination B-cell-associated cytokines might be useful in predicting the immunogenicity of seasonal trivalent influenza vaccine (TIV) in solid organ transplant (SOT) recipients.
METHODS: We performed a subanalysis of a clinical trial that compared the safety and efficacy of high-dose intradermal (ID) versus intramuscular (IM) TIV in SOT recipients. Serum levels of selected cytokines (interferon [IFN]-γ, interleukin [IL]-2, IL-4, IL-5, IL-6, IL-12 and IL-21, and tumor necrosis factor [TNF]-α) were measured pre- and one month post-vaccination in 155 patients (with 84 and 71 receiving the ID and IM vaccines, respectively). Cytokine profiles were compared according to vaccine response (seroconversion [≥4-fold increase in hemagglutination inhibition antibody titers] to ≥1 influenza vaccine antigen).
RESULTS: Mean baseline IL-6 levels were higher (1.20 versus 0.65pg/mL; P-value=0.021) and IL-2 levels were lower (0.01 versus 0.50pg/mL; P-value=0.051) in patients achieving vaccine response. After adjusting for clinical variables, baseline IL-6/IL-2 ratio remained predictive of vaccine response (odds ratio per 10-unit increment: 1.06; 95% confidence interval: 1.02-1.10; P-value=0.002). Vaccination induced an increase in TNF-α (P-value <0.0001) and a decrease in IL-5 levels (P-value=0.0007). There were no significant differences in cytokine kinetics between vaccine responders and non-responders. Mean baseline TNF-α levels were higher in patients experiencing moderate-to-severe adverse events after vaccination (1.93 versus 1.72pg/mL; P-value=0.009).
CONCLUSIONS: Baseline serum IL-6 and IL-2 levels, two cytokines that modulate the role of CD4(+) T follicular helper cells and the terminal differentiation of B-cells, predict vaccine response in SOT recipients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Vaccine - 33(2015), 51 vom: 16. Dez., Seite 7176-7182 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fernández-Ruiz, Mario [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial |
|---|
| Anmerkungen: |
Date Completed 05.10.2016 Date Revised 21.10.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2015.10.134 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM254510302 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM254510302 | ||
| 003 | DE-627 | ||
| 005 | 20231224172529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2015.10.134 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0848.xml |
| 035 | |a (DE-627)NLM254510302 | ||
| 035 | |a (NLM)26555352 | ||
| 035 | |a (PII)S0264-410X(15)01596-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline serum interleukin-6 to interleukin-2 ratio is associated with the response to seasonal trivalent influenza vaccine in solid organ transplant recipients |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2016 | ||
| 500 | |a Date Revised 21.10.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2015 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: The analysis of pre- and post-vaccination B-cell-associated cytokines might be useful in predicting the immunogenicity of seasonal trivalent influenza vaccine (TIV) in solid organ transplant (SOT) recipients | ||
| 520 | |a METHODS: We performed a subanalysis of a clinical trial that compared the safety and efficacy of high-dose intradermal (ID) versus intramuscular (IM) TIV in SOT recipients. Serum levels of selected cytokines (interferon [IFN]-γ, interleukin [IL]-2, IL-4, IL-5, IL-6, IL-12 and IL-21, and tumor necrosis factor [TNF]-α) were measured pre- and one month post-vaccination in 155 patients (with 84 and 71 receiving the ID and IM vaccines, respectively). Cytokine profiles were compared according to vaccine response (seroconversion [≥4-fold increase in hemagglutination inhibition antibody titers] to ≥1 influenza vaccine antigen) | ||
| 520 | |a RESULTS: Mean baseline IL-6 levels were higher (1.20 versus 0.65pg/mL; P-value=0.021) and IL-2 levels were lower (0.01 versus 0.50pg/mL; P-value=0.051) in patients achieving vaccine response. After adjusting for clinical variables, baseline IL-6/IL-2 ratio remained predictive of vaccine response (odds ratio per 10-unit increment: 1.06; 95% confidence interval: 1.02-1.10; P-value=0.002). Vaccination induced an increase in TNF-α (P-value <0.0001) and a decrease in IL-5 levels (P-value=0.0007). There were no significant differences in cytokine kinetics between vaccine responders and non-responders. Mean baseline TNF-α levels were higher in patients experiencing moderate-to-severe adverse events after vaccination (1.93 versus 1.72pg/mL; P-value=0.009) | ||
| 520 | |a CONCLUSIONS: Baseline serum IL-6 and IL-2 levels, two cytokines that modulate the role of CD4(+) T follicular helper cells and the terminal differentiation of B-cells, predict vaccine response in SOT recipients | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Influenza vaccination | |
| 650 | 4 | |a Interleukin-2 | |
| 650 | 4 | |a Interleukin-6 | |
| 650 | 4 | |a Solid organ transplantation | |
| 650 | 4 | |a Vaccine response | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Interleukin-2 |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 700 | 1 | |a Humar, Atul |e verfasserin |4 aut | |
| 700 | 1 | |a Baluch, Aliyah |e verfasserin |4 aut | |
| 700 | 1 | |a Keshwani, Shanil |e verfasserin |4 aut | |
| 700 | 1 | |a Husain, Shahid |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Deepali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 33(2015), 51 vom: 16. Dez., Seite 7176-7182 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2015 |g number:51 |g day:16 |g month:12 |g pages:7176-7182 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2015.10.134 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2015 |e 51 |b 16 |c 12 |h 7176-7182 | ||